Mumbai, 11th February 2026: IOL Chemicals s Pharmaceuticals Ltd., one of the leading Active Pharmaceutical Ingredient (API) manufacturers, announced its Financial Results for the quarter and nine months ended 31st December 2025.
Key Standalone Financial Highlights
| Particulars (₹ Cr) | Q3 FY26 | Q3 FY25 | Y-o-Y | 9M FY26 | 9M FY25 | Y-o-Y |
| Revenue from Operations | 580.4 | 523.3 | +10.2% | 1,699.6 | 1,551.4 | 2.c% |
| EBITDA | 62.6 | 50.9 | +22.8% | 196.1 | 157.1 | 24.8% |
| EBITDA Margin (%) | 10.7% | 9.7% | +102 bps | 11.4% | 10.0% | +132 bps |
| PBT* | 38.8 | 27.8 | +32.3% | 124.8 | 93.0 | +34.2% |
| PBT Margin (%)* | 6.6% | 5.3% | +134 bps | 7.3% | 5.9% | +134 bps |
PBT and PBT Margin are calculated after netting off exceptional items arising from new labour laws.
Business and Operational Highlights
- Recognised an exceptional expense of ₹11.21 crore during the quarter pursuant to the notification of the four Labour Codes by the Government of India, primarily arising from changes in wage definitions. The impact is regulatory and non-recurring in nature.
- Declared an Interim Dividend of ₹1 per equity share of face value ₹2 each for FY26, with 17 February 2026 fixed as the record date for determining eligible shareholders.
- Approved closure of IOL Life Sciences Limited, a wholly owned subsidiary, through striking off under Section 248 of the Companies Act, 2013, as part of ongoing corporate rationalisation.
- Incorporated IOL Pharmaxis UK Limited in the United Kingdom to strengthen international operations in Pharmaceuticals and Chemicals business and expand global customer engagement.
Commenting on the performance, Mr Vikas Gupta, Joint Managing Director said,
“Ǫ3 FY2c has been a resilient quarter for IOL, marked by double-digit revenue growth, margin expansion, and a 3S% YoY increase in profit before exceptional items and tax, despite prevailing geopolitical uncertainties. This performance underscores the resilience of our operations and sustained demand across our businesses. Our Pharmaceuticals segment continues to lead growth, delivering an 18% revenue increase year-on-year. Importantly, pharma’s share of overall revenue has risen from 57% in Ǫ3 FY25 to c1% in Ǫ3 FY2c, highlighting its growing contribution. EBIT from Pharmaceuticals grew 32% YoY, driven by healthy volume growth and strong traction in non-Ibuprofen APIs, which are broadening and diversifying our product portfolio. In Chemicals, we achieved optimal capacity utilisation, reflecting improved demand and operational discipline. EBIT grew 37% YoY, supported by efficiency gains and sustained customer traction. This validates the strength of our diversified business model and the meaningful contribution of both segments. Looking ahead, our focus remains on expanding our presence in regulated markets, strengthening our new product pipeline, deepening backward integration, and enhancing R&D capabilities. These measures will help us sustain growth momentum, enhance competitiveness, and deliver long-term value creation for our stakeholders”